Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ: OCUL) missed Wall Street’s revenue expectations in Q3 2026, with sales falling 11.5% year on year to $12.87 million. Its non-GAAP loss of $0.42 per share was 19.6% below analysts’ consensus estimates.

Is now the time to buy OCUL? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Ocular Therapeutix reported results for the third quarter of 2026 that fell short of Wall Street’s expectations, with management attributing the performance to ongoing investment in late-stage clinical trials and preparations for a major regulatory submission. The market responded negatively to the results, reflecting concerns over the company's widening operating losses and declining sales. CEO Dr. Pravin Dugel described the quarter as “transformational,” emphasizing the critical progress in the company’s AXPAXLI (OTX-TKI) program, including landmark phase III data and alignment with the FDA on the regulatory path. Management pointed to the importance of TKI potency, drug delivery technology, and rigorous clinical design as key differentiators.

Looking ahead, the company’s guidance is anchored by the planned NDA submission for AXPAXLI in wet age-related macular degeneration (AMD) and expectations for broader clinical and commercial milestones through 2027. Management believes that positive outcomes from the ongoing SOL-R and SOL-X studies—along with regulatory engagement—could support both U.S. and international approvals. Dr. Dugel stated, “We remain laser-focused on bringing AXPAXLI, if approved, to patients as quickly as possible,” while the team highlighted ongoing investments in commercial infrastructure and payer engagement. The company’s cash position is expected to support these priorities through the next year, excluding full commercialization costs.

Key insights from management’s remarks

Management attributed the quarter’s underperformance to sustained R&D spending on late-stage AXPAXLI studies and the absence of new product revenues, while emphasizing clinical and regulatory progress as central to the company’s strategic positioning.

• AXPAXLI clinical progress: Ocular Therapeutix advanced its late-stage wet AMD program, with the SOL-1 phase III trial demonstrating both durability and vision maintenance in a challenging patient group. Management highlighted that around two-thirds of patients remained rescue-free for 12 months following a single injection, supporting confidence in the product’s long-term efficacy.
• Regulatory alignment: The company finalized plans for a New Drug Application (NDA) submission for AXPAXLI, citing positive interactions and alignment with the FDA, including agreement on utilizing the 505(b)(2) pathway, which could shorten review timelines compared to traditional new molecular entity submissions.
• Clinical trial design changes: Key modifications were made to the SOL-R study, shifting the primary endpoint from week 56 to week 40 to protect statistical integrity and align with regulatory requirements. Management explained that this change was driven by a desire to avoid operational bias while still exceeding FDA minimum standards for primary endpoint timing in neovascular AMD.
• Data-driven dosing strategy: Updates to the SOL-X extension study included extending dosing intervals from 24 to 48 weeks, reflecting management’s confidence in AXPAXLI’s durability and providing evidence to support potential annual maintenance dosing for stable wet AMD patients.
• Board and leadership updates: The company announced the addition of Dr. Riad Sherif to its Board of Directors, prioritizing commercial expertise as Ocular Therapeutix transitions toward potential product launch and broader market engagement. The board change is seen as a step to strengthen global commercial strategy.

Drivers of future performance

Ocular Therapeutix’s forward outlook is shaped by the timing and outcome of regulatory milestones, ongoing clinical trial readouts, and preparations for the commercial launch of AXPAXLI.

• NDA submission and review: Management expects the planned NDA submission for AXPAXLI in wet AMD to be the most significant short-term milestone. Success in this process, facilitated by FDA alignment and the 505(b)(2) pathway, could accelerate time to potential market entry and enable earlier revenue generation. However, regulatory review remains inherently uncertain, and management acknowledged that additional data from SOL-R and SOL-X may be needed for international approvals.
• SOL-R and SOL-X data readouts: Positive interim safety analysis from SOL-R and long-term durability data from SOL-X are anticipated to support AXPAXLI’s clinical positioning. Management believes these data will not only inform the FDA review but also provide commercial advantages by demonstrating repeat dosing safety and annual maintenance potential. Delays or setbacks in these studies could impact both U.S. and ex-U.S. market opportunities.
• Commercial readiness and payer engagement: The company’s investment in commercial infrastructure and proactive discussions with payers are intended to position AXPAXLI for rapid adoption post-approval. Management highlighted the need to demonstrate cost-effectiveness and durability to secure favorable reimbursement, while flagging that scaling for launch will increase expenses and require disciplined capital allocation.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will focus on (1) progress of the NDA submission and FDA review for AXPAXLI in wet AMD, (2) interim safety and efficacy data from the ongoing SOL-R and SOL-X studies, and (3) developments in commercial infrastructure and payer negotiations that could affect the product’s launch trajectory. Shifts in the competitive landscape or regulatory expectations will also be closely monitored.

Ocular Therapeutix currently trades at $6.91, up from $6.60 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.